Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Long-term Debt

Borrowings due after more than one year.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt rises 124.0% from a year ago

Long-term debt stood at $32.12M at the end of Q1 FY2026, up 124.0% from a year earlier and up 4.5% from the prior quarter. Over 3 fiscal years it compounded at -53.8% a year.

Context

  • Long-term debt amounted to 31.9% of total assets at the end of Q1 FY2026, up 7.6 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +124.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$32.12M+4.5% QoQ
Last fiscal yearDec 2025
$936K-93.5% YoY
Year agoMar 2025
$14.34M+124.0% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+124.0%——
1 year-93.5%——
3-year CAGR-53.8%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
936K USD
Year-over-year change
-93.5%
4-year CAGR
-29.0%

Long-term Debt vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +124.0% is the highest of 3, against a peer median of -34.4%.
  • Long-term debt amounts to 31.9% of total assets for OBIO, versus a peer median of 0.0%.
OBIO Competitors
Long-term Debt for OBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$98.62M USD-22.2%+329.1%31.3%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$32.12M USD+124.0%-53.8%31.9%
IVAInventiva S.A.Dec 2025€24.77M EUR-46.5%-0.9%10.0%
AVTXAvalo Therapeutics, Inc.Mar 2026$2M USD—-47.1%2.0%
TARAProtara Therapeutics, Inc.Mar 2026$1.79M USD——0.9%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
PRLDPrelude Therapeutics IncorporatedMar 2026$0 USD——0.0%
IVVDInvivyd, Inc.Mar 2026$0 USD——0.0%
PYXSPyxis Oncology, Inc.Mar 2026$0 USD——0.0%
TNYATenaya Therapeutics, Inc.Mar 2026$0 USD——0.0%
CRBUCaribou Biosciences, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding OBIO) —-34.4%-0.9%0.0%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents9.94M19.78M30.56M22.26M34.69M
Short-term Investments958K64M57.04M44.55M71.82M
Net Receivables121K96K99K92K95K
Inventory68K276K146K173K310K
Other Current Assets0533K1.27M2.09M994K
Total Current Assets11.32M84.69M89.11M69.17M107.91M
Property, Plant & Equipment (Net)1.12M3.68M2.83M3.49M3.21M
Goodwill00000
Intangible Assets00000
Long-term Investments398K2.5M2.5M2.5M2.5M
Tax Assets00000
Other Non-current Assets690K4.71M769K1.02M1.24M
Total Non-current Assets2.21M10.88M6.1M7M6.95M
Total Assets13.53M95.57M95.21M76.17M114.86M
Account Payables2.03M3.97M2.9M5.13M6.1M
Short-term Debt2M000751K
Tax Payables1K0000
Deferred Revenue5.54M6.44M2.51M4.44M0
Other Current Liabilities2M4.57M2.66M2.61M9.89M
Total Current Liabilities12.24M18.57M11.21M16.21M16.74M
Long-term Debt3.67M9.49M014.29M936K
Deferred Tax Liabilities00(14.92M)00
Deferred Revenue (Non-current)16.86M13.1M14.92M10.99M0
Other Non-current Liabilities51.99M196K14.92M40K33.81M
Total Non-current Liabilities72.52M24.47M15.96M27.01M34.74M
Total Liabilities84.76M43.04M27.17M43.22M51.48M
Common Stock160M2K4K4K6K
Retained Earnings(166.13M)(199.73M)(248.85M)(309.88M)(362.58M)
Accumulated OCI(211.45M)(8K)(10K)52K60K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(71.23M)52.53M68.04M32.96M63.38M
Total Debt5.67M11.87M1.69M16.53M1.69M
Net Debt(4.27M)(7.91M)(28.87M)(5.73M)(33M)

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.